A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

2013 ◽  
Vol 38 (6) ◽  
pp. 433-439 ◽  
Author(s):  
G. M. Hadjigeorgiou ◽  
C. Doxani ◽  
M. Miligkos ◽  
P. Ziakas ◽  
G. Bakalos ◽  
...  
2020 ◽  
Vol 3 (2) ◽  
pp. 167-172
Author(s):  
Sumanta Saha

  Background: Several clinical trials have tested the safety profile of sodium-glucose co-transport inhibitors’ (SGLTis) in adult type 1 diabetes mellitus (T1DM) patients. However, no systematic review has yet compared its variation between large and low dose SGLTis. Henceforth, a review protocol is proposed here to review it. Methods: Different electronic databases will be searched for randomized-controlled trials (published in the English language) studying the above objective, irrespective of their publication date. After selecting the eligible trials, their data on the study design, population characteristics, compared interventions, and outcomes of interest will be extracted. Then, utilizing the Cochrane tool, each trial's risk of selection bias, detection bias, performance bias, attrition bias, reporting bias, and other bias will be judged. Next, depending on clinical heterogeneity among the trials, a random-effect or fixed-effect model meta-analysis will be used to compare the respective outcomes. Via the Chi2 and I2 statistics, the statistical inconsistency among the trials will be estimated. When this is substantial, subgroup analysis will follow. Publication bias will be evaluated by funnel plots and Egger’s test. A sensitivity analysis will be done to check different assumptions. If a quantitative juxtaposition is not possible, a narrative reporting will ensue. Conclusion: The proposed study will perform a dose-wise juxtaposition of the safety profile of SGLTis in insulin-treated T1DM patients. Registration: Prospective Register of Systematic Reviews (PROSPERO) (Registration no. CRD42019146578)    


2021 ◽  
pp. 1-11
Author(s):  
Xiaofan Yuan ◽  
Lei Guo ◽  
Chuan Jiang ◽  
Xu Yang ◽  
Jie Huang

<b><i>Background:</i></b> Despite the vitamin D treatment in patients with multiple sclerosis (MS), there continues to be controversial discrepancy in outcomes according to the current research. Many systematic reviews have evaluated the effect of vitamin D as an adjuvant treatment in patients with MS; however, there is no consensus on the optimum administration time and dosage of vitamin D intake. A meta-analysis for exploring the different administration time and dosage of vitamin D is warranted. <b><i>Methods:</i></b> Randomized controlled trials (RCTs) on the effect of different administration time and dosage of vitamin D in patients with MS were recorded within 7 databases. This meta-analysis was performed with 2 clinical outcomes: EDSS (Expanded Disability Status Scale) and relapses during research. <b><i>Results:</i></b> The pooled results indicated that receiving different administration time and dosage of vitamin D as an adjuvant treatment had no significant therapeutic effect on MS according to the EDSS scores and relapses during research. <b><i>Conclusion:</i></b> According to our meta-analysis, the administration of vitamin D in different dosages (ranging from 2,857 to 14,007 IU/day) and treatment period (ranging from 6 to 24 months) did not affect the clinical outcomes (EDSS and relapses during research) in patients with MS. Additional RCTs should be conducted to explore whether a longer duration and a larger dosage of vitamin D without serious adverse effects might produce therapeutic effects in patients with MS.


2021 ◽  
Author(s):  
Jinchi Jiang ◽  
Chuanqi Chu ◽  
Caie Wu ◽  
Chen Wang ◽  
Chengcheng Zhang ◽  
...  

Preliminary evidence shows the potential role of probiotics in ameliorating multiple sclerosis (MS); however, the effects of probiotics on MS remain unclear.


Drug Safety ◽  
2016 ◽  
Vol 39 (5) ◽  
pp. 409-419 ◽  
Author(s):  
Haixia Li ◽  
Cailian Wang ◽  
Shuo Zhang ◽  
Sihao Sun ◽  
Ruifei Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document